{"id":"t-cell-vaccination","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Pain"}]},"_chembl":{"chemblId":"CHEMBL4298070","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of antigens from cancer cells to T cells, which then recognize and target these cells for destruction. The goal is to induce a long-term immune response against cancer cells.","oneSentence":"T cell vaccination stimulates the body's immune system to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:04.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT07341191","phase":"PHASE2","title":"Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-31","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06482905","phase":"PHASE1","title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","status":"RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2024-09-04","conditions":"High-grade Glioma, WHO Grade Ⅳ Glioma","enrollment":52},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT06784726","phase":"PHASE2","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT07463781","phase":"","title":"Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)","enrollment":100},{"nctId":"NCT07340853","phase":"PHASE1","title":"CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2026-02-28","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06822881","phase":"PHASE1","title":"CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-02-20","conditions":"Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)","enrollment":27},{"nctId":"NCT07458659","phase":"EARLY_PHASE1","title":"Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2026-06-01","conditions":"Relapsed/Refractory Multiple Myeloma (MM)","enrollment":3},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04713046","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16+ Recurrent or Metastatic Cancer","enrollment":24},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06481241","phase":"NA","title":"Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-10","conditions":"Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult","enrollment":77},{"nctId":"NCT06481228","phase":"NA","title":"Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-04","conditions":"Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult","enrollment":82},{"nctId":"NCT05639972","phase":"PHASE1, PHASE2","title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","status":"RECRUITING","sponsor":"Christian Hinrichs","startDate":"2025-08-11","conditions":"HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy","enrollment":15},{"nctId":"NCT03434769","phase":"PHASE1","title":"AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2018-07-09","conditions":"Non-Hodgkin Lymphoma","enrollment":31},{"nctId":"NCT05686226","phase":"PHASE2","title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","status":"RECRUITING","sponsor":"Christian Hinrichs","startDate":"2023-03-07","conditions":"Cervical Cancer, Throat Cancer, Oropharynx Cancer","enrollment":20},{"nctId":"NCT05997264","phase":"PHASE2","title":"Anthrax AV7909 Boost Evaluation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2023-12-05","conditions":"Anthrax","enrollment":220},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT07422896","phase":"PHASE1","title":"A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Catalina Lee Chang","startDate":"2026-06-01","conditions":"Glioblastoma","enrollment":25},{"nctId":"NCT04512716","phase":"EARLY_PHASE1","title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-02","conditions":"B-ALL, DLBCL, B ALL","enrollment":12},{"nctId":"NCT03549325","phase":"NA","title":"A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14","status":"TERMINATED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2017-03-13","conditions":"Meningitis, Meningococcal","enrollment":21},{"nctId":"NCT06789198","phase":"PHASE1","title":"Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-07-08","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":20},{"nctId":"NCT07052305","phase":"PHASE1","title":"NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-02-10","conditions":"Large B-cell Lymphoma","enrollment":24},{"nctId":"NCT05800405","phase":"EARLY_PHASE1","title":"Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-07-20","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":9},{"nctId":"NCT07377435","phase":"PHASE1","title":"DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT07373301","phase":"PHASE2","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","status":"NOT_YET_RECRUITING","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2026-01-19","conditions":"Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention","enrollment":72},{"nctId":"NCT06834373","phase":"PHASE2","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-02","conditions":"Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma","enrollment":41},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT06324240","phase":"PHASE1","title":"Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-12-02","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":18},{"nctId":"NCT06451159","phase":"PHASE1","title":"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bruce Cree","startDate":"2024-06-20","conditions":"Progressive Multiple Sclerosis","enrollment":10},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT04995003","phase":"PHASE1","title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-12-07","conditions":"Sarcoma, HER-2 Protein Overexpression, Osteosarcoma","enrollment":25},{"nctId":"NCT07054931","phase":"PHASE2","title":"Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-05","conditions":"HIV","enrollment":48},{"nctId":"NCT07355972","phase":"EARLY_PHASE1","title":"Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-16","conditions":"SSc-Systemic Sclerosis","enrollment":12},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT07344818","phase":"EARLY_PHASE1","title":"An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-07","conditions":"R/R Aggressive B-cell Lymphoma","enrollment":18},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT07339332","phase":"EARLY_PHASE1","title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-16","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":12},{"nctId":"NCT04545762","phase":"PHASE1","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"C. Babis Andreadis","startDate":"2020-09-11","conditions":"Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT05852717","phase":"PHASE2","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","startDate":"2023-10-31","conditions":"Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer","enrollment":32},{"nctId":"NCT05378464","phase":"PHASE1","title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-05-31","conditions":"HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT06104592","phase":"PHASE2","title":"Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-11-08","conditions":"Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT07316361","phase":"EARLY_PHASE1","title":"GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Endometrial Carcinoma, Endometrial Carcinoma Stage III","enrollment":40},{"nctId":"NCT06879262","phase":"EARLY_PHASE1","title":"Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-02-15","conditions":"R/R NHL","enrollment":60},{"nctId":"NCT07071909","phase":"PHASE1, PHASE2","title":"Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-20","conditions":"Malignancy, Cancer, Hematological Malignancies","enrollment":""},{"nctId":"NCT03277729","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-12-05","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":53},{"nctId":"NCT05260957","phase":"PHASE2","title":"CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).","status":"RECRUITING","sponsor":"Lazaros Lekakis","startDate":"2022-12-14","conditions":"Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma","enrollment":22},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT04670068","phase":"PHASE1","title":"Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-01-27","conditions":"Epithelial Ovarian Cancer","enrollment":4},{"nctId":"NCT07296120","phase":"PHASE4","title":"RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients","status":"NOT_YET_RECRUITING","sponsor":"The Cooper Health System","startDate":"2026-01-01","conditions":"CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic","enrollment":30},{"nctId":"NCT01005745","phase":"NA","title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-10-20","conditions":"Metastatic Melanoma","enrollment":19},{"nctId":"NCT04939402","phase":"NA","title":"SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2021-05-05","conditions":"SARS-CoV-2, Covid19","enrollment":200},{"nctId":"NCT06218602","phase":"PHASE2","title":"Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-19","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT07280494","phase":"PHASE1","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-18","conditions":"CD7+ T-ALL/LBL","enrollment":18},{"nctId":"NCT06156774","phase":"","title":"SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-04-18","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":130},{"nctId":"NCT06649227","phase":"PHASE1","title":"Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-07-10","conditions":"Relapsed Adult AML","enrollment":5},{"nctId":"NCT07261163","phase":"PHASE2","title":"Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-20","conditions":"Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT07002203","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","status":"RECRUITING","sponsor":"Seqker Biosciences, Inc.","startDate":"2024-03-01","conditions":"Solid Tumors, Advanced Cancer, Recurrent Cancer","enrollment":10},{"nctId":"NCT07031713","phase":"PHASE1","title":"Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-07-11","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":12},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT05773859","phase":"PHASE1, PHASE2","title":"NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2023-03-17","conditions":"Epithelial Ovarian Cancer, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT03233854","phase":"PHASE1","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2017-09-01","conditions":"B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease","enrollment":56},{"nctId":"NCT06464185","phase":"PHASE1, PHASE2","title":"A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-30","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":48},{"nctId":"NCT07231081","phase":"PHASE1","title":"Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2025-10-16","conditions":"Solid Tumors","enrollment":85},{"nctId":"NCT07053670","phase":"PHASE1","title":"A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-09","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT05993611","phase":"PHASE1","title":"Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2024-02-19","conditions":"Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease","enrollment":27},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT07103668","phase":"PHASE3","title":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","status":"RECRUITING","sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","startDate":"2025-08-06","conditions":"Gastric Adenocarcinoma","enrollment":150},{"nctId":"NCT00694655","phase":"PHASE4","title":"Human Immune Responses to Yellow Fever Vaccination","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-05","conditions":"Yellow Fever","enrollment":239},{"nctId":"NCT05898464","phase":"PHASE4","title":"Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-06-27","conditions":"Vaccination; Infection, Vaccine Adverse Reaction","enrollment":150},{"nctId":"NCT06854159","phase":"PHASE2","title":"Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-08-07","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":34},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT04410900","phase":"PHASE1","title":"Vaccine Responsiveness After CAR-T Cell Therapy","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-08-03","conditions":"B-Cell Neoplasm","enrollment":49},{"nctId":"NCT07158190","phase":"","title":"Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-06-30","conditions":"Dengue","enrollment":30},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT07153289","phase":"PHASE1, PHASE2","title":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2026-07","conditions":"Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms","enrollment":38},{"nctId":"NCT06799026","phase":"PHASE1","title":"A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"David Avigan","startDate":"2025-01-31","conditions":"Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":25},{"nctId":"NCT05604209","phase":"PHASE1","title":"Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-13","conditions":"HIV Vaccine, HIV-1-infection","enrollment":18},{"nctId":"NCT05828212","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2023-05-15","conditions":"Neuromyelitis Optica","enrollment":9},{"nctId":"NCT04008524","phase":"","title":"A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies","status":"AVAILABLE","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"","conditions":"Relapsed and Refractory Hematological Malignancies","enrollment":""},{"nctId":"NCT07097207","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma","status":"RECRUITING","sponsor":"Shenzhen University General Hospital","startDate":"2023-10-01","conditions":"Relapsed/Refractory B-cell Lymphoma","enrollment":20},{"nctId":"NCT07094477","phase":"PHASE2","title":"Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daihong Liu","startDate":"2025-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT02917083","phase":"PHASE1","title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2017-05-08","conditions":"Hodgkin's Lymphoma, Non-Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT04577326","phase":"PHASE1","title":"Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-30","conditions":"Malignant Pleural Mesothelioma (MPM)","enrollment":14},{"nctId":"NCT07040917","phase":"EARLY_PHASE1","title":"A Study of CAR-T Cells in Subjects With Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-09-30","conditions":"Autoimmune Diseases","enrollment":12},{"nctId":"NCT06900764","phase":"NA","title":"A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-10-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":24},{"nctId":"NCT04645147","phase":"PHASE1","title":"Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-29","conditions":"EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis","enrollment":83},{"nctId":"NCT07051850","phase":"","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2025-07-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma (MM)","enrollment":174},{"nctId":"NCT07049497","phase":"","title":"Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-06-28","conditions":"SAR-CoV-2, Cellular Immune Response, Antibody Response","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":222,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"T cell vaccination","genericName":"T cell vaccination","companyName":"Hadassah Medical Organization","companyId":"hadassah-medical-organization","modality":"Biologic","firstApprovalDate":"","aiSummary":"Researchers have been studying T cell vaccination in various conditions, including COVID-19, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, and HIV Infections, using different interventions such as the hAd5-S-Fusion+N-ETSD vaccine and CD19.CAR-multiVST. The concept of T-cell vaccination involves immunizing against autoreactive T cells, which is analogous to classical vaccination against infectious diseases, but targets a pathogenic T-cell population instead.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}